Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 6, 2005 - Issue 15
Submit an article Journal homepage
77
Views
33
CrossRef citations to date
0
Altmetric
Drug Evaluation

Levosimendan for the treatment of acute heart failure syndromes

John T Parissis Second Cardiology Department and Heart Failure Clinic, Attikon Univesity Hospital, Athens, Greece
,
Gerasimos Filippatos Second Cardiology Department and Heart Failure Clinic, Attikon Univesity Hospital, Athens, Greece
,
Dimitrios Farmakis Second Cardiology Department and Heart Failure Clinic, Attikon Univesity Hospital, Athens, Greece
,
Stamatis Adamopoulos Aftocratoros Irakliou 17, 15122 Maroussi, Athens, Greece. [email protected]
,
Ioannis Paraskevaidis Second Cardiology Department and Heart Failure Clinic, Attikon Univesity Hospital, Athens, Greece
&
Dimitrios Kremastinos Second Cardiology Department and Heart Failure Clinic, Attikon Univesity Hospital, Athens, Greece
Pages 2741-2751 | Published online: 30 Nov 2005

Bibliography

  • MCMURRAY J, PFEFFER MA: New therapeutic options in congestive heart failure. Circulation (2002) 105:2099–2106.
  • KONSTAM MA: Progress in heart failure management? Lessons from the real world. Circulation (2000) 102:1076–1078.
  • PACKER M: Vasodilator and inotropic therapy for severe chronic heart failure: passion and skepticism. J. Am. Coll. CardioL (1983) 2:841–852.
  • PACKER M: The search for the ideal positive inotropic agent. N EngL J. Med. (1993) 329:201–202.
  • MCMURRAY JJ, PFEFFER MA: Heart failure. Lancet (2005) 365:1877–89.
  • ADAMS KF, PATTERSON JH, GATTIS GA et al.: Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis. J. Am. Coll. CardioL (2005) 46:497–504.
  • CHATTERJEE K WOLFE CL, DEMARCO T: Nonglycoside inotropes in congestive heart failure: are they beneficial or harmful? CardioL Clin. (1994) 12:63–72.
  • COLUCCI WS, LEATHERMAN GF, LUDMER PL et al.: O-adrenergic inotropic responsiveness of patients with heart failure: studies with intra-coronary dobutamine infusion. Circ. Res. (1987) 61:182–186.
  • REMONDINO A. KWON SH, COMMUNAL C et al.: Beta-adrenergic receptor-stimulated apoptosis in cardiac myocytes is mediated by reactive oxygen species/c-Jun NH2-terminal kinase-dependent activation of the mitochondrial pathway. Circ. Res. (2003) 92:136–138.
  • HAIKALA H, KAIVOLA J, NISSINEN E et al.: Cardiac troponin C as a target protein for a novel calcium sensitizing drug levosimendan. j MoL Cell. Cardiol. (1995) 27:1859–1866.
  • FIGGIT DP, GILLIES PS, GOA KL: Levosimendan. Drugs (2001) 61:613–627.
  • KIVIKKO M, LEHTONEN L: Levosimendan: a new inodilatory drug for the treatment of decompensated heart failure. Cuff. Pharmac. Des. (2005) 11:435–455.
  • BRIXIUS K, REICKE S, SCHWINGER RH: Beneficial effects of the Ca2+ sensitizer levosimendan in human myocardium. Am. J. PhysioL Heart Circ. PhysioL (2002) 282:H131–H137.
  • HAIKALA H, POLLESELLO P: Calcium sensitivity enhancers. Drugs (2000) 3:1199–1205.
  • PERRONE S, KAPLINSKY EJ: Calciumsensitizer agents: a new class of inotropic agents in the treatment of decompensated heart failure. Int. J. CardioL (2005) 103:248–255.
  • ERHARDT L: An emerging role for calcium sensitization in the treatment of heart failure. Expert Opin. Investig. Drugs. (2005) 14(6):659–670.
  • HAIKALA H, LINDEN IB: Mechanisms of action of calcium-sensitizing drugs. Cardiovasc. PharmacoL (1995) 26\(Suppl. 1):S10–519.
  • PAPP Z, CSAPO K, POLLESELLO P et al.: Pharmacological mechanisms contributing to the clinical efficacy of levosimendan. Cardiovasc. Drug Rev. (2005) 23(1):71–98.
  • •An excellent overview of experimental and clinical studies that describe the levosimendan efficacy and safety in acute heart failure syndromes.
  • HAIKALA H, KAHEINEN P, LEVIJOKI J et al.: The role of cAMP- and cGMP-dependent protein kinases in the cardiac actions of the new calcium sensitizer, levosimendan. Cardiovasc. Res. (1997) 34:536–546.
  • SORSA, T, HEIKKINEN S, ABOTT MB et al.: Binding of levosimendan, a calcium sensitizer, to cardiac troponin C. Biol. Chem. (2001) 276:9337–9343.
  • POLLESELLO P, OVASKA M, KAIVOLA J et al.: Binding of a new Ca2+ sensitizer, levosimendan, to recombinant human cardiac troponin C. A molecular modeling, fluorescence probe, and proton nuclear magnetic resonance study. Biol. Chem. (1994) 269:28584–28590.
  • LEVIJOKI J, POLLESELLO P, KAIVOLA J et al.: Further evidence for the cardiac troponin C mediated calcium sensitization by levosimendan: structure-response and binding analysis with analogs of levosimendan. J. MoL Cell. CardioL (2000) 32:479–491.
  • HASENFUSS G, PIESKE B, KRETSCHMANN B et al.: Effects of calcium sensitizers on intracellular calcium handling and myocardial energetics. Cardiovasc. Pharmacol. (1995) 26\(Suppl. 1):545–551.
  • POLLESELLO P, MEBAZAA A: ATP-dependent potassium channels as a key target for the treatment of myocardial and vascular dysfunction. Curr. Opin. Crit. Care (2004) 10(6):436–41.
  • YOKOSHIKI H, KATSUBE Y, SUNAGAWA M et al.: Levosimendan, a novel Ca2+ sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocytes. Eur. j PharmacoL (1997) 333:249–259.
  • PATARICZA J, KRASSOI K, HOHN J et al.: Functional role of potassium channels in the vasodilating mechanism of levosimendan in porcine isolated coronary artery. Cardiovasc. Drugs Ther. (2003) 17(2):115–21.
  • KERSTEN JR, MONTGOMERY WM, PAGEL PS et al.: Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of K(ATP) channels. Anesth. Analg. (2000) 90(1):5–11.
  • DU TOIT E, HOFMANN D, MCCARTHY J et al.: Effect of levosimendan on myocardial contractility, coronary and peripheral blood flow, and arrhythmias during coronary artery ligation and reperfusion in the in vivo pig model. Heart (2001) 86(1):81–87.
  • TASSANI P, SCHAD H, HEIMISCH W et al.: Effect of the calcium sensitizer levosimendan on the performance of ischaemic myocardium in anaesthetized pigs. Cardiovasc. Drugs Ther. (2002) 16(5):435–441.
  • MICHAELS AD, MC KEOWN B, KOSTAL M et al.: Effects of intravenous levosimendan on human coronary vasomotor regulation, left ventricular wall stress, and myocardial oxygen uptake. Circulation. (2005) 111(12):1504–1509.
  • GROSSINI E, CAIMMI PP, MOLINARI C et aL: Haemodynamic effect of intracoronary administration of levosimendan in the anesthetized pig. Cardiovasc. Pharmacol. (2005) 46:333–342.
  • KOPUSTINSKIENE DM, POLLESELLO P, SARIS NE: Potassium-specific effects of levosimendan on heart mitochondria. Biochem. Pharmacol. (2004) 68(5):807–812.
  • O'ROURKE B: Evidence for mitochondrial K+ channels and their role in cardioprotection. Circ. Res. (2004) 94:420–432.
  • SONNTAG S, SUNDBERG S, LEHTONEN Let aL: The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia. J. Am. Coll. CardioL (2004) 43:2177–2182.
  • DE LUCA L, PROIETTI P, CELOTTO A et al.: Levosimendan improves haemodynamics and coronary flow reserve after percutaneous coronary intervention in patients with acute myocardial infarction and left ventricular dysfunction. Am. Heart J. (2005) 150(3):563–568.
  • MAYTIN M, COLUCCI W: Cardioprotection: a new paradigm in the acute management of acute heat failure syndromes. Am. J. CardioL (2005) 96(6A):26G–31G.
  • •An excellent review focusing on in vitro studies regarding the anti-apoptotic and cardioprotective role of levosimendan in the failing myocardium.
  • MC BRIDE BF, WHITE M: Levosimendan; implications for clinicians.J. Clin. Pharmacol. (2003) 43:1071–1081.
  • CLELAND JGF, MC GOWAN J: Levosimendan: a new era for inodilator therapy for heart failure? Cuff. Opin. CardioL (2002) 17:257–265.
  • SANDELL EP, HAYHA M, ANTILA S et al.: Pharmacokinetics of levosimendan in healthy volunteers and patients with congestive heart failure. J. Cardiovasc. Pharmacol. (1995) 26:S57–S62.
  • KIVIKKO M, ANTILA S, EHA J et aL: Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure. Int. J. Clin. Pharmacol. Ther. (2002) 40(10):465–471.
  • TAKAHASHI R, TALUKDER MA, ENDOH M: Effects of OR-1896, an active metabolite of levosimendan, on contractile force and aequorin light transients in intact rabbit ventricular myocardium. J. Cardiovasc. Pharmacol. (2000) 36(1):118–125.
  • ANTILA S, HUUSKONEN H, NEVALAINEN T et aL: Site dependent bioavailability and metabolism of levosimendan in dogs. Eur J. Pharm. Sci. (1999) 9(1):85–91.
  • NIEMINEN M, AKKILA J, HASENFUSS G et aL: Haemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J. Am. Coll. CardioL (2000) 36(61:1903–1912.
  • LEHTONEN L, SUNDBERG S: The contractility enhancing effect of the calcium sensitizer levosimendan is not attenuated by carvedilol in healthy subjects. Eur. j Clin. Pharmacol. (2002) 58(7):449–452.
  • PODER P, ANTILA S, EHA J et al.: Pharmacodynamic interactions of levosimendan and felodipine in patients with coronary heart disease. Cardiovasc. Drugs Ther. (2003) 17(5-6):451–458.
  • ANTILA S, JARVINEN A, HONKANEN T et aL: Pharmacokinetic and pharmacodynamic interactions between the novel calcium sensitiser levosimendan and warfarin. Eur. J. Clin. Pharmacol. (2000) 56(9-14705–710.
  • HARJOLA V-P, PEUHKURINEN K, NIEMINEN MS et aL: Oral levosimendan improves cardiac function and haemodynamics in patients with severe heart failure. Am. J. Cardiol. (1999) 83:4(1)–8(1).
  • PODER P, EHA J, SUNDBERG S et al.: Pharmacodynamics and pharmacokinetics of oral levosimendan and its metabolites in patients with severe congestive heart failure: a dosing interval study. J. Clin. Pharmacol. (2004) 44:1143–1150.
  • SLAWSKY MT, COLUCCI WS, GOTTLIEB S et aL: Acute haemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation (2000) 102:2222–2227.
  • ••A randomised dose-escalation studydemonstrating levosimendan-induced improvement of central haemodynamics in advanced heart failure patients.
  • KYRZOPOULOS S, ADAMOPOULOS S, PARISSIS J et aL: Levosimendan reduces plasma B-type natriuretic peptide and interleukin-6, and improves central haemodynamics in severe heart failure patients. Int. J. CardioL (2005) 99:409–413.
  • MOERTL D, BERGER R, HUELSMANN M et aL: Short-term effects of levosimendan and prostaglandin El on haemodynamic parameters and B-type natriuretic peptide levels in patients with decompensated chronic heart failure. Eur. J. Heart Fail. (in press).
  • LABRIOLA C, SIRO-BRIGIANI M, CARRATA F et al.: Haemodynamic effects of levosimendan in patients with low-output heart failure after cardiac surgery. Int. J. Clin. Pharmacol. Ther. (2004) 42:204–211.
  • SIPILA-WARIS K, SUOJARANTA-YLINEN R, HARPOLA V-P: Levosimendan in cardiac surgery. J. Cardiothorac. Vasc. Anesth. (2005) 19:345–349.
  • LILLEBERG J, NIEMINEN MS, AKKILA J et al.: Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary bypass grafting. Eur. Heart J. (1998) 19:660–668.
  • FOLLATH F, FRANCO F, CARDOSO JS: The European experience on the practical use of levosimendan in patients with acute heat failure syndromes. Am. J. CardioL (2005) 96(6A):80G–85G.
  • NANAS JN, PAPAZOGLOU PP, TERROVITIS JV et al.: Haemodynamic effects of levosimendan added to dobutamine in patients with decompensated advanced heart failure refractory to dobutamine alone. Am. J. CardioL (2004) 94:1329–1332.
  • JANSSEN PML, DATZ N, ZEITZ O et al.: Levosimendan improves diastolic and systolic function in failing human myocardium. Eur. j PharmacoL (2000) 404:191–199.
  • •An experimental study demonstrating for the first time the beneficial effects of levosimendan on diastolic function of failing hearts.
  • HAIKALA H, NISSINEN E, ETEMADZADEH E et al.: Troponin-C mediated calcium sensitization induced by levosimendan does not impair relaxation. J. Cardiovasc. PharmacoL (1995) 25:794–801.
  • PAGEL PS, MC COUGH, HETTRICK DA et al.: Levosimendan enhances left ventricular systolic and diastolic function in conscious dogs with pacing-induced cardiomyopathy. J. Cardiovasc. PharmacoL (1997) 29:563–573.
  • TACHINABA H, CHENG HJ, UKAI T et al.: Levosimendan improves LV systolic and diastolic performance at rest and during exercise after heart failure. Am. J. PhysioL Heart Circ. PhysioL (2005) 288:H914–H922.
  • PARISSIS J, PANOU F, FARMAKIS D et al.: Effects of levosimendan on markers of left ventricular diastolic function and neurohormonal activation in patients with advanced heart failure. Am. J. CardioL (2005) 96:423–426.
  • DERNELLIS J, PAPAPETROU M: Effects of levosimendan on restrictive left ventricular filling in severe heart failure: a combined haemodynamic and Doppler echocardiographic study. Chest (2005) 128(4):2633–2639.
  • COMMUNAL C, SIGNH K, PIMENTEL DR et al.: Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the beta-adrenergic pathway. Circulation (1998) 98:1329–1334.
  • ZHU WZ, WANG SQ, CHAKIR K et aL: Linkage of beta 1-adrenergic stimulation to apoptotic heat cell death through protein kinase A-independent activation of Ca2+/ calmodulin kinase II. J. Clin. Invest. (2003) 111:617–625.
  • PARISSIS J, ADAMOPOULOS S, ANTONIADES C et aL: Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure. Am. J. CardioL (2004) 93:1309–1312.
  • •The first in vivo study demonstrating anti-inflammatory and anti-apoptotic effects of levosimendan in advanced heart failure.
  • ADAMOPOULOS S, PARISSIS J, KREMASTINOS D: A glossary of circulating cytokines in chronic heart failure. Eur. j Heart. Fail. (2001) 3:517–526.
  • AVGEROPOULOU C, ANDREADOU I, MARKADONIS-KYROUDIS S et al.: The Ca2+-sensitizer levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine. Eur. J. Heart Fail. (2005) 7:882–887.
  • PARASKEVAIDIS I, PARISSIS J, KREMASTINOS D: Anti-inflammatory and anti-apoptotic effects of levosimendan in decompensated heart failure: a novel mechanism of drug-induced improvement in contractile performance of the failing heart. Curr. Med. Chem. Cardiovasc. HematoL Agents (2005) 3:243–247.
  • MOISEYEV VS, PODER P, ANDREJEVS N et al.: RUSSLAN Study Investigators. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur. Heart. J. (2002) 23:1422–1432.
  • ••Multi-centre trial demonstrating survivalbenefits of levosimendan versus placebo in patients with acute heart failure in the post-infarction setting.
  • FOLLATH F, CLELAND JG, JUST H et al.: Steering Committee and Investigators of the Levosimendan Infusion versus Dobutamine (LIDO) Study. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomized double-blind trial. Lancet (2002) 360:196–202.
  • ••The first randomised multi-centre trialdemonstrating superiority of levosimendan versus dobutamine in haemodynamic improvement and survival benefit of patients with decompensated heart failure.
  • COLETTA AP, CLELAND JF, FREEMANTLE N et al.: Clinical trials update from the European Society of Cardiology Heart Failure Meeting: SHAPE, BRING-UP 2VAS, COLA II, FOSIDIAL, BETACAR, CASINO and meta-analysis of cardiac resynchronization therapy. Eur. J. Heart Fail. (2004) 6:673–676.
  • PACKER M, COLUCCI WS, FISHER L et al.: Development of a comprehensive new end-point for the evaluation of new treatments for acute decompensated heart failure: results with levosimendan in the REVIVE-1 study. J. Card. Fail. (2003) 9:S61 Abstr.
  • MEBAZAA A, BARRAUD D, WELSCHBILLIG S: Randomized clinical trials with levosimendan. Am. J. CardioL (2005) 96(6A):74G–79G.
  • PARISSIS J, FARMAKIS D, KREMASTINOS D: Anti-inflammatory effects of levosimendan in decompensated heart failure. Am. J. CardioL (2005) 95:923–924.
  • ULLEBERG J, YLONEN LEHTONEN Let al.: The calcium sensitizer levosimendan and cardiac arrhythmias: an analysis of the safety database of heart failure treatment studies. Scand. Cardiovasc. J. (2004) 38:80–84.
  • TOIVONEN L, VITASALO M, SUNDBERG S et al.: Electrophysiologic effects of calcium sensitizer inotrope levosimendan administered intravenously in patients with normal cardiac function. Cardiovasc. Pharmacol (2000) 35:664–669.

Websites

  • http://www.orion.fi/english/investors/ stockreleases.shtml/a05?23290 Orion stock exchange release: Abbott reports improved clinical course with Orion's levosimendan (Simdax(D) when added to standard therapy in acute decompensated heart failure trial (REVIVE-2). Accessed 16 November, 2005.
  • http://www.orion.fi/english/investors/ stockreleases.shtml/a05?23304 Orion stock exchange release: Abbott reports levosimendan (Simdax(D) results from large mortality trial in patients with acute decompensated heart failure (SURVIVE). Accessed 16 November, 2005.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.